9/12/2018. Zoster. Herpes Zoster (Shingles) Complications of Herpes Zoster
|
|
- Katrina Hopkins
- 5 years ago
- Views:
Transcription
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Zoster September 2018 Chapter 22 Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rightsare implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Herpes Zoster (Shingles) Reactivation of varicella zoster virus Generally occurs unilaterally in the distribution of a sensory nerve Most often the trunk or 5 th cranial nerve Associated with: Aging Immunosuppression Intrauterine exposure Varicella disease younger than 18 months of age Complications of Herpes Zoster Dissemination with generalized skin eruptions and involvement of the central nervous system, lungs, liver, and pancreas Postherpetic neuralgia (PHN) Ophthalmic zoster 1
2 Zoster involving the ophthalmic division of the trigeminal nerve Herpes Zoster 500,000 to 1 million episodes occur annually in the United States Lifetime risk of zoster estimated to be 32% 50% of persons living until age 85 will develop zoster Zoster Vaccines Product FDA AgeIndications ACIP Abbreviation Zostavax 50 years and older* (Note: ACIP recommended at 60 years and older) ZVL Shingrix 50 years and older RZV *Zostavaxis FDA-approved for persons 50 years of age and older 2
3 Live Zoster Vaccine (ZVL) Efficacy Vaccine recipients 60 to 80 years of age had 51% fewer episodes of zoster Efficacy declines with increasing age Significantly reduces the risk of postherpetic neuralgia Reduces the risk of zoster 69.8% in persons 50 through 59 years of age RZV Vaccine Efficacy Efficacy for the prevention of zoster: 96.6% in adults age 50 to 59 years 97.4% in adults age 60 to 69 years 91.3% in adults age 70 years and older The efficacy for the prevention of postherpetic neuralgia (PHN) was: 91.2% in adults age 50 years and older 88.8% in adults age 70 years and older CDC ShingrixInformation for Healthcare Professionals accessed 8/12/2018 Vaccine Efficacy and Effectiveness against HZ for HZ/suand ZVL, by Age Group, During the First 4 Years Following Vaccination VE % yrs yrs 70 + yrs HZ/su (ZOE 50/70)^ ZVL (RCTs*) ZVL (Baxter 2017) ZVL (Izurieta 2017) Median follow-up may be less than 3 yrs: Schmader 2012= 1.3 yrs ^ZOE 50/70= and 60-69yr: Lal 2015, 70+yrs: Cunningham 2016 *RCTs= yrs: Schmader 2012, and 70+ yrs: Oxman 2005, 32 3
4 Acceptable Evidence of Varicella Immunity Written documentation of age-appropriate vaccination Laboratory evidence of immunity or laboratory confirmation of varicella disease U.S.-born before 1980* Health care provider diagnosis or verification of varicella disease History of herpes zoster based on health care provider diagnosis *Birth year immunity criterion does not apply to health care personnel or pregnant women MMWR 2007;56(RR-4):16-17 ACIP Zoster Immunization Recommendations Administer 2 doses of Shingrixto immunocompetent persons 50 years of age and older Regardless of previous history of: o Vaccination with varicella-containing vaccines Varivax or Zostavax ozoster disease Shingrixis preferred to Zostavaxfor persons 60 years and older Separate varicella-containing vaccines and Shingrixby at least 8 weeks MMWR 2018;67(3): Zoster Vaccination: Patients Who Do Not Report APrior Episode of Varicella When vaccinating adults 50 years of age and older, there is no need to: Screen for a history of varicella (chickenpox) infection OR Conduct laboratory testing for serologic evidence of prior varicella infection More than 99% of adults age 50 years and older worldwide have been exposed to varicella zoster virus ACIP considers people born in the United States prior to 1980 immune to varicella MMWR 2018;67(3):
5 Zoster Vaccine and Serology If tested and varicella-negative: Administer 2 doses of single-antigen varicella vaccine (Varivax) separated by at least 4 weeks Followed by 2 doses of RZV, separated by 2 6 months oseparate the 2 nd (last) dose of varicella and 1 st dose of RZV by at least 8 weeks MMWR 2008;57(RR-5) Zoster Vaccine Administration Preparation Zoster vaccine: Reconstitute just prior to administration Use the diluent supplied by the vaccine s manufacturer Zostavax Route: Subcut injection Site: Upper outer triceps of the arm or the thigh may be used if necessary Needle gauge: gauge Needle length: 5/8 inch Shingrix Route: IM injection Site: Deltoid or the thigh may be used if necessary Needle gauge: gauge Needle length: Varies by age/weight Zostavax Vaccine Contraindications Severe allergic reaction to a vaccine component or following a prior dose Pregnancy or planned pregnancy within 4 weeks * Immunosuppression including those with HIV infection *ACIP off-label recommendation 5
6 Zostavax(ZVL) Vaccine Precautions Moderate or severe acute illness Current treatment with an antiviral drug active against herpes viruses Discontinue at least 24 hours before administration of zoster vaccine Should not be taken for at least 14 days after vaccination Recent receipt of a blood product is NOT a precaution MMWR 2008;57(RR-5) RZV Contraindications and Precautions History of severe allergic reaction, such as anaphylaxis, to any component of a vaccine or after a previous dose of Shingrix Moderate to severe illness, including an acute episode of herpes zoster Shingrixis not a treatment for herpes zoster or postherpetic neuralgia (PHN) Shingrixhas not been studied in pregnant women or women who are breastfeeding. Providers should consider delaying Shingrix vaccination for these women CDC ShingrixRecommendations accessed 8/12/2018 RZV and Immunosuppressive Therapy Administer RZV to persons: Taking low-dose immunosuppressive therapy (e.g., <20 mg/day of prednisone or equivalent or using inhaled or topical steroids) Anticipating immunosuppression Who have recovered from an immunocompromising illness ACIP has not yet made recommendations regarding use RZV in these patients Persons on moderate to high doses of immunosuppressive therapy were excluded from RZV efficacy studies MMWR 2018;67(3):
7 Zostavax(ZVL) Adverse Reactions Local reactions 34% (pain, erythema) No increased risk of fever No serious adverse reactions identified MMWR 2008;57(RR-5) RZV (Shingrix) Adverse Reactions Local reactions 49% Local reactions Grade 3 9.4% Systemic reactions (headache, malaise, fatigue) Systemic reactions (headache, malaise, fatigue) Grade % 11% MMWR 2018;67(3): Adverse Reactions after Shingrix Educate patients regarding: Potential adverse reactions, including injection site and systemic reactions The need for a second dose even if s/he has an adverse reaction Offer comfort measures and strategies CDC unpublished photo. Used with the permission of the patient. 7
8 Vaccine Information Statements There is a VIS for: ZVL (Zostavax) RZV (Shingrix) Var(Varicella) MMRV (ProQuad) Give the parent or patient the appropriate VIS for the product that will be administered Vaccine Information Statements accessed 8/12/2018 Real-Life ShingrixAdministration Errors Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine 13 (8%) of the 155 reports to VAERS regarding Shingrixdocumented a vaccine administration error MMWR 2018;67:20 Shingrix Vaccine Administration Errors Vaccine administration errors reported to VAERS include: Wrong route: Subcutroute rather than the IM Wrong age: Administered to persons less than 50 years of age Wrong vaccine: Shingrix instead of varicella (Varivax) vaccine Improper storage: Administered after frozen storage Wrong preparation: Administered the adjuvanted diluent only Wrong schedule: Interval violations between doses of Shingrixor a previous dose of varicella-containing vaccine Other errors we have heard about: Staff unaware of the need for a second dose Staff thinks Zostavaxcan count toward completing the 2-dose Shingrixseries 8
9 Storage and Handling: Zostavax Store lyophilized component in a freezer between -58 F and +5 F (-50 C and -15 C) * In the original packaging with the lids closed Protect vaccine from light In a clearly labeled bin and/or area of the storage unit Store diluent in a refrigerator or at room temperature Do NOT freeze diluent Use ONLY the manufacturer-supplied diluent to reconstitute the lyophilized vaccine *Zostavaxmay be stored and transported in a refrigerator between 36 F and 46 F (2 C and 8 C) for up to 72 continuous hours after removal from freezer. Discard unused vaccine after 72 hours. Vaccine storage label example available at Storage and Handling: Shingrix Store both vaccine and diluent at refrigerator temperature 2 C and 8 C (36 F and 46 F) Store vaccine and diluent in the original packaging with the lids closed in a clearly labeled bin and/or area of the storage unit Use ONLY the manufacturer-supplied diluent to reconstitute the lyophilized vaccine Vaccine storage label example available at Varicella and Zoster Vaccine Resources and References Resources and references are available on the webinar web page 9
10 PLEASE PLACE QUESTIONS IN THE BASKET 10
Varicella (Chickenpox) and Varicella Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Varicella (Chickenpox) and Varicella Vaccines September 2018 Photographs and images included in this
More informationShingles: What s New to Know
This material was prepared by the New England Quality Innovation Network-Quality Improvement Organization (NE QIN-QIO), the Medicare Quality Improvement Organization for New England, under contract with
More informationDisclosures. I have no financial interests in immunizations discussed here. I may discuss off-label use of licensed vaccines
2/28/18 Disclosures I have no financial interests in immunizations discussed here I may discuss off-label use of licensed vaccines Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) epidemiology, United
More information9/11/2018. HPV Yoga. Human Papillomavirus. Human Papillomavirus (HPV) Disease. Most common sexually transmitted infection in the U.S.
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Human Papillomavirus September 2018 Chapter 11 Photographs and images included in this presentation
More information9/10/2018. General Best Practice Guidelines. General Recommendations. General Recommendations on Immunization
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases General Best Practice Guidelines on Immunization Part Two Chapter 2 September 2018 Photographs and images
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More informationShingrix (zoster vaccine recombinant, adjuvanted) NEW PRODUCT SLIDESHOW
Shingrix (zoster vaccine recombinant, adjuvanted) NEW PRODUCT SLIDESHOW Introduction Brand name: Shingrix Generic name: Zoster vaccine recombinant, adjuvanted Pharmacological class: Shingles vaccine Strength
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationHERPES ZOSTER This resource is designed to offer pharmacists a concise and accurate tool to support assessing,
PHARMACISTS HELPING PROTECT PATIENTS FOCUS ON HERPES ZOSTER This resource is designed to offer pharmacists a concise and accurate tool to support assessing, recommending, and administering vaccines to
More informationWhat You Should Know about the 2018 Adult Immunization Schedule & New Recommendations
What You Should Know about the 2018 Adult Immunization Schedule & New Recommendations Adult Immunization Conference April 10, 2018 Susan M. Lett, M.D., MPH Medical Director Immunization Program Massachusetts
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE Revisions as of /4/10 Zostavax should not be given concomitantly with Pneumovax 3 due to reduced immune response to Zostavax.
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Update on Adult Immunization Strategies: Understanding the Current Recommendations EDWARD A. DOMINGUEZ, MD, FACP, FIDSA Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical Center,
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More information9/11/2018. Polio and Polio Vaccine. Poliomyelitis Disease. Poliovirus. First outbreak described in the U.S. in 1843
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Polio and Polio Vaccine Chapter 18 September 2018 Photographs and images included in this presentation
More informationImmunization Update 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2018 Dane County Immunization Coalition JoEllen Wolicki, RN, BSN Nurse Educator
More informationGeneral Recommendations. General Best Practice Guidelines 9/10/2018. General Best Practice Guidelines for Immunization Part 1
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases General Best Practice Guidelines for Immunization Part 1 Chapter 2 September 2018 Photographs and images
More informationTo provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More information9/11/2018. Rotavirus. Rotavirus. Rotavirus. First identified as a cause of diarrhea in 1973
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Rotavirus September 2018 Photographs and images included in this presentation are licensed solely for
More informationIMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine
IMMUNIZATION PROTOCOLS FOR PHARMACISTS VARICELLA Live Virus Vaccine I. ORDER: 1. Screen for contraindications and evidence of immunity (Section VII.K.) 2. Provide a current Vaccine Information Statement
More informationWhat You Should Know about the 2018 Immunization Schedule & New Recommendations
What You Should Know about the 2018 Immunization Schedule & New Recommendations AAP Webinar April 19, 2018 Susan M. Lett, M.D., MPH Medical Director Immunization Program Massachusetts Department of Public
More information2018 Adult Immunization Schedule
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases 2018 Adult Immunization Schedule National Adult Immunization Coordinators Partnership Quarterly Meeting
More informationWhat s New With Immunizations
What s New With Immunizations 2018 Annual Update COURTNEY A. ROBERTSON, PHARMD, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF LOUISIANA AT MONROE COLLEGE OF PHARMACY Disclosures No financial disclosures
More information9/12/2018. Influenza and Influenza Vaccines. Influenza. Influenza Virus. Highly infectious viral illness. First pandemic in 1580
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Influenza and Influenza Vaccines Adult Track Photographs and images included in this presentation are
More informationNew Herpes Zoster Vaccine Shingrix Expected to Become Available for Vaccines for Adults (VFA) Sites in July 2018
June 25, 2018 New Herpes Zoster Vaccine Shingrix Expected to Become Available for Vaccines for Adults (VFA) Sites in July 2018 Vaccine pre-release guidance for VFA program enrolled sites Background On
More informationAdvisory Committee on Immunization Practices Meeting Update
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Advisory Committee on Immunization Practices Meeting Update June 2017 JoEllen Wolicki, BSN, RN Nurse
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationImmunization Update 2018
Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts
More information9/12/2018. Assessing Adult Immunization History and Needed Vaccines. Standards for Adult Immunization Practice
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Assessing Adult Immunization History and Needed Vaccines September 2018 Photographs and images included
More information9/11/2018. Measles. Measles, Mumps, and Rubella. Measles Complications. Paramyxovirus Nasopharynx is primary site of infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Measles, Mumps, and Rubella September 2018 Chapters 13, 15 and 20 Photographs and images included in
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More informationImmunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist
Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Sunday CME Breakfast Update on Adult Immunization Strategies: Understanding the Current Recommendations Edward Dominguez, MD Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SHINGRIX safely and effectively. See full prescribing information for SHINGRIX. SHINGRIX (Zoster
More information9/11/2018. Influenza and Influenza Vaccines. Influenza. Influenza Virus. Highly infectious viral illness. First pandemic in 1580
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Influenza and Influenza Vaccines September 2018 Photographs and images included in this presentation
More informationWelcome to the CIC Education Hour
Welcome to the CIC Education Hour Shingles Vaccine 2.0: What you need to know Objectives Explain the clinical benefits and recommendations for administration of Shingrix, the new shingles vaccine Explain
More informationQuality ID #474: Zoster (Shingles) Vaccination National Quality Strategy Domain: Community/Population Health Meaningful Measure Area: Preventive Care
Quality ID #474: Zoster (Shingles) Vaccination National Quality Strategy Domain: Community/Population Health Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES
More informationZostavax vaccine: now fully subsidised
Dermatology Infections Older person s health Virology Zostavax vaccine: now fully subsidised Zostavax is a herpes zoster (shingles) vaccine that will become fully subsidised from 1 April, 2018 for people
More informationLes 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies
Les 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies VZV Epidemiology and Pathogenesis 98% adults Respiratory spread 1,000,000/year and increasing CMI continuously boosted
More informationZOSTAVAX Zoster Vaccine Live Lyophilized preparation for subcutaneous injection
9815603 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZOSTAVAX 1 safely and effectively. See full prescribing information for ZOSTAVAX. ZOSTAVAX
More informationOverview of Immunizations for People Who Work in Labs
Overview of Immunizations for People Who Work in Labs CLMA/ASCLMS Spring Meeting Little Rock, AR April 5, 2019 Jennifer Dillaha, MD Medical Director, Immunizations Medical Advisor, Health Literacy Arkansas
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE
Kenneth McCall, BSPharm, PharmD Associate Professor UNE Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize each of the CDC recommended flu vaccines
More information9/11/2018. Tdap/Td Vaccines. Why Adolescents and Adults Need Pertussis Vaccine. Pertussis Complications Among Adolescents and Adults
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Tdap/Td Vaccines September 2018 Chapters 7, 21 and 16 Photographs and images included in this presentation
More informationImmunizations: new and sometimes confusing recommendations MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE AND RADY CHILDREN S HOSPITAL SAN DIEGO
Immunizations: new and sometimes confusing recommendations MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE AND RADY CHILDREN S HOSPITAL SAN DIEGO Disclosures I have no financial disclosures related to this
More informationBackground Rationale for resource
Slide 1 Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering
More informationEmerging Issues in Reactivated Herpes Zoster Disease
Emerging Issues in Reactivated Herpes Zoster Disease Tim Hilderman, MD FRCPC 2018 Infection Prevention and Control Across the Continuum Friday, June 22 nd, 2018 DISCLOSURE STATEMENT Type of relationship
More informationHot off the press, What s new for immunizations in 2017?
Hot off the press, What s new for immunizations in 2017? Jennifer Girotto, PharmD, BCPPS Faculty Disclosure Dr. Girotto has no actual or potential conflicts of interest associated with this presentation.
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationDiphtheria, Tetanus, and Pertussis. DTaP/DT and Tdap/Td Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Diphtheria, Tetanus, and Pertussis DTaP/DT and Tdap/Td Vaccines Jean C. Smith, MD, MPH Medical Officer
More informationBackground Rationale for resource
Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering a
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01B adjuvanted) Suspension for Injection Read this
More informationImmunizations for Health Care Workers
Immunizations for Health Care Workers Tanisha Taylor, MD, MPH Senior Medical Director Barnabas Health Corporate Care Tanisha Taylor MD, MPH Senior Medical Director Barnabas Health Corporate Care CDC Immunizations
More informationUpdate ACIP Influenza Vaccination Recommendations for
Update ACIP Influenza Vaccination Recommendations for 2014-15 Lisa Grohskopf, MD, MPH Influenza Division, CDC IAC Webinar 11 September 2014 National Center for Immunization and Respiratory Diseases Influenza
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationVaccinating Adults: A Step-by-Step Guide
Vaccinating Adults: A Step-by-Step Guide step ₁ : getting started The Basics 1 6 Why the emphasis on adult vaccination? 3 How do I determine which vaccines adults need? 5 The Guide does not discuss vaccines
More informationImmunization Updates, Vaccine Administration, and Safety. Audrey Muñoz, LVN, AAHA Immunization Educator June 20, 2012
Immunization Updates, Vaccine Administration, and Safety Audrey Muñoz, LVN, AAHA Immunization Educator June 20, 2012 Immunization Schedules Use all three schedules: 0-6 years, 7-18 years, and the Catch-Up
More informationInfluenza, Pneumococcal and Herpes Zoster Vaccination
Influenza, Pneumococcal and Herpes Zoster Vaccination Chris Campanile, MD, Ph.D Clinical Consultant, Healthcentric Advisors Clinical Associate Professor of Family Medicine, Brown University Alpert Medical
More informationHERPES ZOSTER VACCINATION
HERPES ZOSTER VACCINATION Herpes Zoster (shingles) is a reactivation of the varicella zoster infection in some-one who has previously had varicella(chicken pox) disease Painful, unilateral, self-limiting
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Registration No.: 1C 10/54 (NBC) Importer / Manufacturer: MSD (Thailand) Ltd. / Merck Sharp & Dohme Corp., West Point, Pennsylvania 19486, USA SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL
More informationApproximately 25% of people develop shingles during their lifetime, with the majority of cases occurring in those over 50 years of age.
ÜNZÜLE ALPASLAN WHAT IS SHINGLES? Shingles is an infection of an individual nerve and the skin surface that is supplied by the nerve; it is caused by the varicella-zoster virus - the same virus that causes
More informationHot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC
Hot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC Infectious Diseases Consultant Island Health Authority Clinical Assistant Prof of Med, UBC Victoria Faculty/Presenter Disclosure Wayne
More informationA Call To Arms: The Basics for Select Vaccines
Page 1 A Call To Arms: The Basics for Select Vaccines A Call To Arms: The Basics for Select Vaccines Wendy Rosenthal, Pharm.D. A Call To Arms: The Basics for Select Vaccines Vaccine Science Basics of Immunity
More informationThe introduction of a vaccine for people aged 70 years (routine cohort) and 79 years (catch up cohort) to protect against shingles
The introduction of a vaccine for people aged 70 years (routine cohort) and 79 years (catch up cohort) to protect against shingles An update for registered healthcare professionals December 2013 Quality
More informationIn Case of Technical Difficulties
Shingles Vaccines: What You Need to Know Wednesday, December 6, 2017 12:00 PM ET In Case of Technical Difficulties If you hear an echo: Make sure you are only logged in once on your computer Select one
More informationUpdate on Immunizations and the Shingles Vaccine
Update on Immunizations and the Shingles Vaccine Conflict of Interest Disclosure I have no conflicts of interest to disclose. Sarah Scoular, PharmD., BCPS Annual Meeting 2018 Objectives 1. Describe the
More informationTimely Immunization Practice Strategies
Timely Immunization Practice Strategies Mary Wisinski RN BSN Immunization Program Supervisor March 9, 2018 Slide Credits Credit for many slides to the Michigan Department of Health and Human Services Immunization
More informationImmunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE Update as of 06 2010 Addition of IXIARO, Inactivated, Adsorbed vaccine; grown in tissue culture
More informationHealthcare Personnel Immunization. Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville
Healthcare Personnel Immunization Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville Disclosures Funding provided by the U. S. Department of Homeland
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (Zoster Vaccine Live) Suspension for
More informationVaccine Label Examples
Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can
More informationIn Case of Technical Difficulties
Updates from October 2017 ACIP Meeting Thursday, November 9, 2017 12:00 PM ET In Case of Technical Difficulties If you hear an echo: Make sure you are only logged in once on your computer Select one form
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association
Kenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize
More informationVaccination to protect against shingles
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2018 and contraindications and precautions Revised July 2018 NES and HPS accept
More informationZoster Vaccine for Older Adults
BC Centre for Disease Control IMMUNIZATION FORUM 29 Zoster Vaccine for Older Adults Michael N. Oxman, M.D. Professor of Medicine and Pathology University of California, San Diego VASDHS Staff Physician
More informationInfluenza Clinical Bulletin # 3: October 8, 2009 Vaccination Guidelines for Patients for Influenza
The purpose of this document is to provide NYP providers with the most current recommendations regarding influenza vaccination for their patients. It is important to recognize that guidance reflects optimal
More informationShingles vaccination for those aged 70 to 79
Shingles vaccination for those aged 70 to 79 Shingles affects a lot of people as they get older. It often causes severe pain which can last for months or sometimes years. Shingles is more common and more
More informationOREGON PUBLIC HEALTH DIVISION IMMUNIZATION PROTOCOL FOR PHARMACISTS RABIES INACTIVATED VIRUS VACCINE FOR PRE-EXPOSURE PROPHYLAXIS ONLY
OREGON PUBLIC HEALTH DIVISION IMMUNIZATION PROTOCOL FOR PHARMACISTS RABIES INACTIVATED VIRUS VACCINE FOR PRE-EXPOSURE PROPHYLAXIS ONLY Review 06-2010 No changes to the PRE-EXPOSURE protocol of 2008. See
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationImmunization with Influenza Vaccine (Inf)
Immunization with Influenza Vaccine (Inf) Background Influenza is a respiratory infection caused by either the type A or type B influenza viruses, and occurs in populations worldwide. Although it is generally
More informationADMINISTERING VACCINATIONS AT OFFSITE LOCATIONS
ADMINISTERING VACCINATIONS AT OFFSITE LOCATIONS Purpose: To reduce morbidity and mortality for all vaccine-preventable diseases by administering routinely recommended vaccines to children and adults who
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationImmunization Update: Shingles, Mumps and Best Practice Oh my!!!
Immunization Update: Shingles, Mumps and Best Practice Oh my!!! Kevin W. Cleveland, PharmD, ANP Assistant Dean and Associate Professor Idaho State University College of Pharmacy February 2018 Disclosure
More information6/29/2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018
Disclosure Statement New Drugs I have no conflicts of interest to disclose Steven Walden, PharmD, MPH WellCare Health Plans Manager, Clinical Implementations Learning Objectives At the completion of this
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (Zoster Vaccine Live) Suspension for
More informationShingles vaccination for those aged 70 to 79
Shingles vaccination for those aged 70 to 79 Shingles affects a lot of people as they get older. It often causes severe pain which can last for months or sometimes years. Shingles is more common and more
More informationBackground Rationale for resource Note: Shingles is also known as herpes zoster. For the purpose of this resource the
Slide 1 Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering
More informationUpdate on Immunizations H. Keipp Talbot, M.D., M.P.H.
Update on Immunizations H. Keipp Talbot, M.D., M.P.H. Vanderbilt University Medical Center 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding from Sanofi
More informationPatient Immunization FAQ Sheet
Patient Immunization FAQ Sheet Shingles Vaccine: Q: Who should get the shingles vaccine (Zostavax )? A: Anyone 60 years of age or should get the shingles (herpes zoster) vaccine. There is no maximum age
More informationMake No Mistake: Vaccine Storage/Handling & Administration
Make No Mistake: Vaccine Storage/Handling & Administration JoEllen Wolicki, BSN, RN National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Adult and
More informationAged 70 or 78? There s now a vaccine to help protect you against shingles
Aged 70 or 78? There s now a vaccine to help protect you against shingles This leaflet describes shingles and the benefits of the vaccination. The new shingles vaccine is being phased in over the next
More informationAdult Immunization Update 2017 Including Influenza General Best Practice Guidelines for Immunization
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Adult Immunization Update 2017 Including Influenza General Best Practice Guidelines for Immunization
More informationDilemmas in Zoster Eye Disease Stephanie Klemencic, OD, FAAO
Dilemmas in Zoster Eye Disease Stephanie Klemencic, OD, FAAO Please silence all mobile devices and remove items from chairs so others can sit. Unauthorized recording of this session is prohibited. Disclosure
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More information10/16/2018. Be Discuss. Describe. Discuss. Discuss 2018 ADULT IMMUNIZATION SCHEDULE INFLUENZA ADULT IMMUNIZATION UPDATE TRAINING OBJECTIVES FLUMIST
ADULT IMMUNIZATION UPDATE NORTH DAKOTA ACADEMY OF FAMILY PHYSICIANS NOVEMBER 10, 2018 Be Discuss Upon completion of the adult immunization training, participants will be able to: Discuss the general adult
More information